1. Home
  2. VRTX vs METAM Comparison

VRTX vs METAM Comparison

Compare VRTX & METAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$517.10

Market Cap

135.6B

Sector

Technology

ML Signal

N/A

METAM

Meta Platforms Inc. Depositary Shares representing a 1/20th Interest in a Share of Series A Mandatory Convertible Preferred Stock

N/A

Current Price

$46.42

Market Cap

125.8B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
VRTX
METAM
Founded
1989
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Computer Software: Programming Data Processing
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
135.6B
125.8B
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
VRTX
METAM
Price
$517.10
$46.42
Analyst Decision
Buy
Analyst Count
32
0
Target Price
★ $595.36
N/A
AVG Volume (30 Days)
1.3M
★ 2.8M
Earning Date
11-02-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 836.54
N/A
EPS
10.90
★ 20.44
Revenue
$2,488,652,000.00
★ $40,653,000,000.00
Revenue This Year
$10.46
N/A
Revenue Next Year
$10.53
N/A
P/E Ratio
$47.77
★ $2.38
Revenue Growth
46.20
★ 47.09
52 Week Low
$412.27
$48.58
52 Week High
$568.67
$52.09

Technical Indicators

Market Signals
Indicator
VRTX
METAM
Relative Strength Index (RSI) 41.75 19.58
Support Level $493.75 N/A
Resistance Level $536.58 $52.09
Average True Range (ATR) 15.90 1.33
MACD -3.73 -0.41
Stochastic Oscillator 4.74 7.19

Price Performance

Historical Comparison
VRTX
METAM

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Share on Social Networks: